Bioactive ripid ;Concened with MM

生物活性细腻；与MM一致

• 批准号: 24701036
• 负责人: TANAKA Yuko
• 金额: $ 2.83万
• 依托单位: Tokyo Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2012
• 资助国家: 日本
• 起止时间: 2012-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24701036/
• 关键词: multile myeloma; sphingosine-1 phosphate; fingolimod; sphingosine 1-phasphate; 多発性骨髄腫; ABC294640; sphingosine1phosphate; multiple myeloma

multiple myeloma (MM),which is one of B-lymphocyte neoplasma, is not curable disease in spite of establishing new theraputic strategy.Therefore it is necessary to develop more excellent treating for the disease.To that end, it is require to elucidating pathophysiology in a new beginning.In pathology of multiple myeloma, the role of sphingosine-1 phosphate(S1P) is not revealed yet. On the other hand the function of S1P for cell biology gradually becomes clear. S1P plays important role of cell proliferation, survival, apoptosis, and migration. Indeed S1P is known to be concerned with the cell proliferation and developing of malignant tumors. In this study we try to reveal the relevance with MM and S1P for developing new therapeutic strategy.

多发性骨髓瘤（multiple myeloma， MM）是b淋巴细胞肿瘤的一种，尽管有新的治疗策略，但仍是一种无法治愈的疾病。因此，有必要开发更优良的治疗方法。为此，需要在新的起点上阐明病理生理学。在多发性骨髓瘤病理中，鞘氨醇-1磷酸（S1P）的作用尚未明确。另一方面，S1P在细胞生物学中的作用逐渐清晰。S1P在细胞增殖、存活、凋亡和迁移中起重要作用。事实上，已知S1P与恶性肿瘤的细胞增殖和发展有关。在这项研究中，我们试图揭示与MM和S1P的相关性，以制定新的治疗策略。

项目成果

Therapeutic potential of targeting sphingosine-1-phosuphate and sphingosine kinases in multiple myeloma

靶向 1-磷酸鞘氨醇和鞘氨醇激酶在多发性骨髓瘤中的治疗潜力

• 发表时间: 2013
• 作者: Tanaka Y;Okabe S;Ohyashiki K
• 通讯作者: Ohyashiki K

Therapeutic Potential of Targeting Sphingosine-1 Phosphate and Sphingosine Kinases in Multiple Myeloma Cells

靶向 1 磷酸鞘氨醇和鞘氨醇激酶在多发性骨髓瘤细胞中的治疗潜力

• 发表时间: 2013
• 作者: Yuko Tanaka,Seiichi Okabe;Tetsuzo Tauchi
• 通讯作者: Tetsuzo Tauchi

Serum sphingosine-1 phospate is possible to be an available biomarker for multiple myeloma

血清 1 磷酸鞘氨醇可能成为多发性骨髓瘤的可用生物标志物

• 发表时间: 2013
• 作者: 田中裕子;岡部聖一;伊藤良和;田内哲三;大屋敷一馬
• 通讯作者: 大屋敷一馬

Serum sphingosine-1-phosphate is possible to be an available biomarker for multiple myeloma

血清 1-磷酸鞘氨醇可能成为多发性骨髓瘤的可用生物标志物

• 发表时间: 2013
• 作者: Tanaka Y;Okabe S;Ohyashiki K
• 通讯作者: Ohyashiki K

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.

• DOI: 10.1371/journal.pone.0089080
• 发表时间: 2014
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Okabe S;Tauchi T;Kimura S;Maekawa T;Kitahara T;Tanaka Y;Ohyashiki K
• 通讯作者: Ohyashiki K